Published in Medical Letter on the CDC and FDA, September 14th, 2008
The two NM100060 clinical studies were randomized, double-blind and placebo-controlled, and designed to assess the efficacy, safety and tolerability of NM100060 in patients with mild to moderate toenail onychomycosis (nail fungus). No significant adverse event was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA